Avanos Medical Inc (AVNS) concluded trading on Thursday at a closing price of $12.43, with 0.46 million shares of worth about $5.7 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -45.48% during that period and on April 17, 2025 the price saw a gain of about 3.07%. Currently the company’s common shares owned by public are about 45.96M shares, out of which, 44.82M shares are available for trading.
Stock saw a price change of 0.00% in past 5 days and over the past one month there was a price change of -16.13%. Year-to-date (YTD), AVNS shares are showing a performance of -21.92% which decreased to -33.35% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $11.91 but also hit the highest price of $25.36 during that period. The average intraday trading volume for Avanos Medical Inc shares is 503.86K. The stock is currently trading -7.45% below its 20-day simple moving average (SMA20), while that difference is down -15.11% for SMA50 and it goes to -34.84% lower than SMA200.
Avanos Medical Inc (NYSE: AVNS) currently have 45.96M outstanding shares and institutions hold larger chunk of about 94.52% of that.
The stock has a current market capitalization of $571.82M and its 3Y-monthly beta is at 1.16. It has posted earnings per share of -$8.53 in the same period. It has Quick Ratio of 1.53 while making debt-to-equity ratio of 0.21. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AVNS, volatility over the week remained 3.85% while standing at 4.12% over the month.
Stock’s fiscal year EPS is expected to drop by -16.67% while it is estimated to increase by 12.89% in next year. EPS is likely to grow at an annualized rate of 1.94% for next 5-years, compared to annual growth of -54.63% made by the stock over the past 5-years.
Coverage by CL King stated Avanos Medical Inc (AVNS) stock as a Buy in their note to investors on May 22, 2023, suggesting a price target of $31 for the stock. On August 04, 2021, Stephens Downgrade their recommendations, while on April 13, 2020, Barclays Upgrade their ratings for the stock with a price target of $30. Stock get a Hold rating from Stifel on November 07, 2019.
